News

The facility, which is expected to start operations in 2017, will manufacture about 40 million packs and 850 million tablets of around 30 medicines every year. It represents

The company expects to complete the study in the second half of 2016. It is a multi-center, single-arm, open-label trial in healthy women at least 18 years old

Inotuzumab ozogamicin is an investigational antibody-drug conjugate (ADC), which features a monoclonal antibody (mAb) targeting CD22,9 cell surface antigen expressed on about 90% of B-cell malignancies,10 linked to

The trial, which will also include study sites in Europe and Australia, is designed to identify whether the company’s pancreatic cancer treatment (Cell-in-a-Box capsules + low-doses ifosfamide chemotherapy)

This phase IIa study is a randomized, open-label, three-arm study of AL-335, a nucleotide-based HCV NS5B polymerase inhibitor, odalasvir, an HCV NS5A inhibitor and simeprevir, an HCV NS3/4A

MERS was initially found in Saudi Arabia in 2012. It is an illness caused by a coronavirus known as the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Hemispherx said

Specifically, NICE recommended Daklinza, an oral, once-daily medication used in combination with other agents, to treat certain patients with HCV genotypes 1, 3 and 4. Approximately 214,000 people

Trabodenoson, which is the company’s lead clinical candidate, is being investigated to reduce intraocular pressure. About 335 patients diagnosed with primary open-angle glaucoma (POAG) or ocular hypertension (OHT)

The CRL states that additional clinical information is required to support the company’s new drug application (NDA). It includes clinical trial data from ongoing or completed studies and